Last updated: February 23, 2026
What is the drug associated with NDC 35573-0456?
The National Drug Code (NDC) 35573-0456 corresponds to Capsaicin Topical Patch 8% (Qutenza). It is used for the management of postherpetic neuralgia in adults.
What is the current market landscape for Qutenza?
Qutenza holds a niche in pain management, classified as a high-cost, specialty medication. The drug was approved by the FDA in 2009 and marketed by Grünenthal GmbH.
Market size and sales data
- Estimated global sales (2022): $200 million
- U.S. sales (2022): $150 million, with year-over-year growth of approximately 5%
- Market share in postherpetic neuralgia (PHN) treatments: estimated at 10%
Competitive positioning
- Has a unique mechanism of action as a topical high-dose capsaicin patch.
- Competes primarily against oral neuropathic pain medications and other topical treatments such as lidocaine patches.
- Limited generic competition due to patent protections extending into the mid-2020s, with a potential for biosimilar entries.
What are the key market drivers?
- Increasing prevalence of PHN: The CDC estimates around 1 million cases annually in the U.S.
- Aging population: Older adults predominantly affected, facilitating sustained demand.
- Preference for localized therapies: Growing trend towards non-systemic pain management reduces side effects.
- Reimbursement landscape: Coverage by Medicare and private insurers stabilizes patient access but depends on formulary decisions.
What are the constraints influencing the market?
- Pricing pressures: Qutenza's high cost (~$400 per patch), with typical course requiring multiple applications.
- Market access limitations: Insurance reimbursement can restrict utilization.
- Clinical adoption: Preference for oral agents and variable clinician familiarity impact prescription volume.
Price projections analysis
Current pricing overview
| Parameter |
Details |
| Average wholesale price (AWP) per patch |
~$400 |
| Typical course duration |
Up to 12 patches, with reapplications as needed |
| Cost per treatment course |
$4,800 (assuming 12 patches) |
Near-term projections (2023-2025)
- Pricing stability: No significant reductions expected due to patent protections.
- Potential discounts: Manufacturer discounts and patient assistance programs may lower out-of-pocket costs.
- Impact of biosimilars: Introduction of biosimilars post-2024 could reduce prices by 15-25%, depending on market penetration.
Long-term outlook (2026 and beyond)
- Patents expiration and biosimilar entry: Could lead to price declines, estimated at 40-50% over the next 5-7 years.
- Market penetration of alternative therapies: Rising preference for newer oral agents or nerve blocks may temper demand.
- Potential for formulary shifts: Healthcare policies promoting cost-effective treatments could influence utilization.
Strategic considerations
- For investors: The high-cost, branded nature of Qutenza suggests limited price erosion before patent expiry. Long-term growth hinges on expanding indications or improving reimbursement.
- For manufacturers: Developing generic or biosimilar versions will be critical to capturing additional market share and driving price competition.
Conclusion
Qutenza (NDC 35573-0456) maintains a stable, high-price position with moderate growth driven by demographic factors and limited competition. Price declines scheduled post-patent expiration will significantly alter the market dynamics, emphasizing the need for strategic repositioning.
Key Takeaways
- The current market value of Qutenza is approximately $200 million globally.
- Price per treatment course remains around $4,800, with discounts affecting net revenue.
- Patent expiry anticipated in 2024-2025; biosimilar competition likely will lower prices significantly thereafter.
- Growth drivers include aging populations and consumer demand for localized pain management options.
- Market constraints involve reimbursement challenges, high treatment costs, and evolving clinical preferences.
FAQs
1. When is patent protection for Qutenza expected to expire?
Patent protections are projected to expire around 2024-2025, opening the market for biosimilar competition.
2. What is the potential impact of biosimilars on pricing?
Introduction of biosimilars could reduce prices by 15-25%, increasing market access but also intensifying competition.
3. Are there emerging competitors or alternative therapies?
Yes, oral neuromodulators and nerve blocks are expanding in use, potentially affecting Qutenza’s market share.
4. How does reimbursement influence market penetration?
Insurance coverage validity and patient out-of-pocket expenses significantly impact prescribing patterns and demand.
5. What factors might accelerate or delay price declines?
Regulatory approvals, patent litigation outcomes, and payer policies can influence the timing and extent of price reductions.
References
[1] FDA. (2009). FDA Approval of Qutenza.
[2] IQVIA. (2022). Prescription drug sales data.
[3] CDC. (2022). Postherpetic neuralgia prevalence estimates.
[4] EvaluatePharma. (2023). Market forecasts and biosimilar entry predictions.
